Protocol to synthesize sequence-controlled glycooligomers for tumor targeting in mice

• Published in: STAR protocols 2024-06, Vol.5 (2), p.103029, Article 103029
• Main Authors: Lin, Qina, Chen, Jie, Zhang, Yichuan, Gao, Quan, Zhu, Liwei, Xing, Qi, Geng, Jin
• Format: Article
• Language: English
• Subjects: Animals; Cancer; Cell Line, Tumor; Chemistry; Humans; Mice; Model Organisms; Neoplasms; Oligosaccharides - chemistry; Protocol
• ISSN: 2666-1667; 2666-1667
• DOI: 10.1016/j.xpro.2024.103029

Due to the higher and more rapid consumption of carbohydrates by cancer cells compared to normal cells, carbohydrates can be effectively employed as a targeted therapeutic strategy for tumor treatment. Here, we present a protocol for synthesizing sequence-controlled glycooligomers using both solution-phase and solid-phase systems. We outline detailed procedures for evaluating the safety and tumor-targeting properties of the sequence-controlled glycooligomers in vivo. For complete details on the use and execution of this protocol, please refer to Chen et al.1 [Display omitted] •Synthesis of azide, silyl-alkyne, and saccharide glycooligomer blocks•Synthesis of sequence-controlled glycooligomers in both solid-phase and solution-phase systems•In vivo study of sequence-controlled glycooligomers using the LoVo tumor model Publisher’s note: Undertaking any experimental protocol requires adherence to local institutional guidelines for laboratory safety and ethics. Due to the higher and more rapid consumption of carbohydrates by cancer cells compared to normal cells, carbohydrates can be effectively employed as a targeted therapeutic strategy for tumor treatment. Here, we present a protocol for synthesizing sequence-controlled glycooligomers using both solution-phase and solid-phase systems. We outline detailed procedures for evaluating the safety and tumor-targeting properties of the sequence-controlled glycooligomers in vivo.